Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis

Xiao Feng Le, Walter N. Hittelman, Jiaxin Liu, Amanda McWatters, Chun Li, Gordon Mills, Robert C. Bast

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The 70kDa ribosomal S6 kinase (p70S6K) is important for cell growth and survival. Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones. Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration- and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody. Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel. Paclitaxel-induced p70S6KT421/S424 phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca++, PI3K, and mammalian target of rapamycin (mTOR). Despite phosphorylation of p70S6KT421/S424, paclitaxel inactivates this kinase in a concentration- and time-dependent manner as illustrated by in vitro kinase assay. Inhibitors of mTOR, PI3K, and Ca++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation. Moreover, the paclitaxel-induced phosphorylation and low activity of p70S6K mainly occurs during mitosis. In summary, paclitaxel is able to induce p70S6KT421/S424 phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways. Our data suggest that paclitaxel-induced p70S6KT421/S424 phosphorylation and kinase inactivation are differentially regulated. Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.

Original languageEnglish (US)
Pages (from-to)484-497
Number of pages14
JournalOncogene
Volume22
Issue number4
DOIs
StatePublished - Jan 30 2003
Externally publishedYes

Fingerprint

70-kDa Ribosomal Protein S6 Kinases
Paclitaxel
Mitosis
Phosphorylation
Threonine
Serine
Phosphotransferases
Sirolimus
Phosphatidylinositol 3-Kinases
Phosphoamino Acids
Ribosomal Protein S6 Kinases
MAP Kinase Signaling System
Antibodies
Mitogen-Activated Protein Kinase 1
Microtubules
Ovarian Neoplasms
Growth Hormone
Cell Survival
Intercellular Signaling Peptides and Proteins
Western Blotting

Keywords

  • Activation
  • Mitosis
  • P70S6K
  • Paclitaxel
  • Phosphorylation

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. / Le, Xiao Feng; Hittelman, Walter N.; Liu, Jiaxin; McWatters, Amanda; Li, Chun; Mills, Gordon; Bast, Robert C.

In: Oncogene, Vol. 22, No. 4, 30.01.2003, p. 484-497.

Research output: Contribution to journalArticle

Le, Xiao Feng ; Hittelman, Walter N. ; Liu, Jiaxin ; McWatters, Amanda ; Li, Chun ; Mills, Gordon ; Bast, Robert C. / Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. In: Oncogene. 2003 ; Vol. 22, No. 4. pp. 484-497.
@article{f6001941cba549a09d10e88214515653,
title = "Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis",
abstract = "The 70kDa ribosomal S6 kinase (p70S6K) is important for cell growth and survival. Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones. Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration- and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody. Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel. Paclitaxel-induced p70S6KT421/S424 phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca++, PI3K, and mammalian target of rapamycin (mTOR). Despite phosphorylation of p70S6KT421/S424, paclitaxel inactivates this kinase in a concentration- and time-dependent manner as illustrated by in vitro kinase assay. Inhibitors of mTOR, PI3K, and Ca++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation. Moreover, the paclitaxel-induced phosphorylation and low activity of p70S6K mainly occurs during mitosis. In summary, paclitaxel is able to induce p70S6KT421/S424 phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways. Our data suggest that paclitaxel-induced p70S6KT421/S424 phosphorylation and kinase inactivation are differentially regulated. Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.",
keywords = "Activation, Mitosis, P70S6K, Paclitaxel, Phosphorylation",
author = "Le, {Xiao Feng} and Hittelman, {Walter N.} and Jiaxin Liu and Amanda McWatters and Chun Li and Gordon Mills and Bast, {Robert C.}",
year = "2003",
month = "1",
day = "30",
doi = "10.1038/sj.onc.1206175",
language = "English (US)",
volume = "22",
pages = "484--497",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis

AU - Le, Xiao Feng

AU - Hittelman, Walter N.

AU - Liu, Jiaxin

AU - McWatters, Amanda

AU - Li, Chun

AU - Mills, Gordon

AU - Bast, Robert C.

PY - 2003/1/30

Y1 - 2003/1/30

N2 - The 70kDa ribosomal S6 kinase (p70S6K) is important for cell growth and survival. Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones. Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration- and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody. Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel. Paclitaxel-induced p70S6KT421/S424 phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca++, PI3K, and mammalian target of rapamycin (mTOR). Despite phosphorylation of p70S6KT421/S424, paclitaxel inactivates this kinase in a concentration- and time-dependent manner as illustrated by in vitro kinase assay. Inhibitors of mTOR, PI3K, and Ca++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation. Moreover, the paclitaxel-induced phosphorylation and low activity of p70S6K mainly occurs during mitosis. In summary, paclitaxel is able to induce p70S6KT421/S424 phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways. Our data suggest that paclitaxel-induced p70S6KT421/S424 phosphorylation and kinase inactivation are differentially regulated. Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.

AB - The 70kDa ribosomal S6 kinase (p70S6K) is important for cell growth and survival. Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones. Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration- and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody. Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel. Paclitaxel-induced p70S6KT421/S424 phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca++, PI3K, and mammalian target of rapamycin (mTOR). Despite phosphorylation of p70S6KT421/S424, paclitaxel inactivates this kinase in a concentration- and time-dependent manner as illustrated by in vitro kinase assay. Inhibitors of mTOR, PI3K, and Ca++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation. Moreover, the paclitaxel-induced phosphorylation and low activity of p70S6K mainly occurs during mitosis. In summary, paclitaxel is able to induce p70S6KT421/S424 phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways. Our data suggest that paclitaxel-induced p70S6KT421/S424 phosphorylation and kinase inactivation are differentially regulated. Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.

KW - Activation

KW - Mitosis

KW - P70S6K

KW - Paclitaxel

KW - Phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=0037473081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037473081&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206175

DO - 10.1038/sj.onc.1206175

M3 - Article

C2 - 12555062

AN - SCOPUS:0037473081

VL - 22

SP - 484

EP - 497

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 4

ER -